Market Overview

Afternoon Market Gainers

Share:
Related BLUE
Roth Capital: Buy The Dips In Bluebird Bio
Kite Pharma CEO: 'We Are Offering The Next Generation Immunotherapy'
Related NKTR
Baxalta's BAX 855 Pivotal Data Published in Blood Shows Potential to Provide Strong Bleed Prevention with Twice Weekly Dosing for Patients with Hemophilia A
Mid-Morning Market Update: Markets Open Lower; Lennar Beats Q2 Estimates

Bluebird Bio (NASDAQ: BLUE) traded up 49.55 percent to $25.41. Wednesday's IPO for the company was initially priced at $17.

Nektar Therapeutics (NASDAQ: NKTR) rose 9.99 percent to $10.79 after announcing positive top-line results from a human abuse liability (HAL) study for NKTR-181.

Gevo (NASDAQ: GEVO) climbed 9.23 percent to $2.26 after yesterday's announcement that it had resumed commercial production of Isobutanol.

Keryx BioPharma (NASDAQ: KERX) shot up 6.50 percent to $8.16 after analysts at JP Morgan initiated coverage on the stock with an Overweight rating.

MannKind (NASDAQ: MNKD) regained 6.48 percent to $7.03 after yesterday's double-digit drop.

Posted-In: News Movers

 

Related Articles (GEVO + BLUE)

Get Benzinga's Newsletters